Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada
Current Oncology · 2025
DOI: 10.3390/curroncol32080444 ↗Kurz gefasst
Leitlinie in der Zeitschrift Current Oncology, 2025. Verfasst von Katarzyna J Jerzak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly (Canada), Karamjeet Singh, PhD and Andrea Brumwell, PhD of MEDUCOM Health Inc., Eli Lilly Canada Inc..
Abstract (Originalsprache)
Cyclin-dependent kinase (CDK)4/6 inhibitors have become a key component of adjuvant treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer who are at high risk of recurrence. The addition of abemaciclib and ribociclib to standard endocrine therapy has demonstrated clinically meaningful improvements in invasive disease-free survival, supported by the monarchE and NATALEE trials, respectively. With expansion of patient eligibility for CDK4/6 inhibitors, multidisciplinary coordination among medical oncologists, surgeons, nurses, pharmacists, and other health care providers is critical to optimizing patient identification, monitoring, and management of adverse events. This expert guidance document provides practical recommendations for implementing adjuvant CDK4/6 inhibitor therapy in routine clinical practice, incorporating insights from multiple specialties and with patient advocacy representation. Key considerations include patient selection based on clinical trial data, treatment duration, dosing schedules, adverse event profiles, monitoring requirements, drug–drug interactions, and patient-specific factors such as tolerability, cost, and quality of life. This guidance aims to support Canadian clinicians in effectively integrating CDK4/6 inhibitors into clinical practice, ensuring optimal patient outcomes through a multidisciplinary and patient-centric approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
- Department of Surgery, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
- Department of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
- Grand River Regional Cancer Centre, Kitchener, ON N2G 1G3, Canada.
- Dr. H. Bliss Murphy Cancer Centre, St. John's, NL A1B 3V6, Canada.
ORCID-Profile: Christine Brezden-Masley, Nadia Califaretti, Jan-Willem Henning, Nathalie LeVasseur
Förderung
- Eli Lilly (Canada)
- Karamjeet Singh, PhD and Andrea Brumwell, PhD of MEDUCOM Health Inc.
- Eli Lilly Canada Inc.
Zitieren
APA
Jerzak, K. J., Sehdev, S., Boileau, J. F., Brezden-Masley, C., Califaretti, N., Edwards, S., Gordon, J., Henning, J. W., LeVasseur, N., & Railton, C. (2025). Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Current Oncology. https://doi.org/10.3390/curroncol32080444
Vancouver
Jerzak KJ, Sehdev S, Boileau JF, Brezden-Masley C, Califaretti N, Edwards S, et al. Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Current Oncology. 2025. doi:10.3390/curroncol32080444
BibTeX
@article{Jerzak2025,
author = {Jerzak, Katarzyna J and Sehdev, Sandeep and Boileau, Jean-François and Brezden-Masley, Christine and Califaretti, Nadia and Edwards, Scott and Gordon, Jenn and Henning, Jan-Willem and LeVasseur, Nathalie and Railton, Cindy},
title = {Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32080444}
}
EUVIMED